Premium
Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non‐Hodgkin lymphoma
Author(s) -
Barth Matthew J.,
MinardColin Veronique
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15783
Subject(s) - medicine , lymphoma , oncology , refractory (planetary science) , chemotherapy , disease , hodgkin lymphoma , immunology , toxicity , biology , astrobiology
Summary Non‐Hodgkin lymphomas ( NHL s) are a heterogeneous group of malignancies. Most NHL s in children, adolescent and young adult patients are aggressive lymphomas that are generally treated with multi‐agent chemotherapy or immunochemotherapy regimens. While overall survival is high, the treatment can lead to a high rate of acute and long‐term toxicity. However, in the rarer instance of relapsed or refractory disease, outcomes are dismal. Novel therapeutic approaches to the treatment of both T‐cell and B‐cell NHL s are critical to improve outcomes while also minimising the associated toxicity of current treatment regimes. Potential therapeutic approaches in development include humoral and cellular immunotherapies, small molecule inhibitors of relevant signalling pathways and epigenetic modifying agents. In this review, we will highlight the current state of development of agents of interest with a focus on agents relevant to childhood, adolescent and young adult NHL .